Cetuximab

New treatment strategies for HPV-positive head and neck cancer

Barbara Kofler, Simon Laban, Chia‐Jung Busch, Balázs B. Lőrincz, Rainald Knecht

Citations: 67 • 2013

Identification of a novel ATM inhibitor with cancer cell specific radiosensitization activity

Amy J.C. Dohmen, Xiaohang Qiao, Anja Duursma, Ruud H. Wijdeven, Cor Lieftink, Floor Hageman, Ben Morris, Pasi Halonen, Conchita Vens, Michiel W. M. van den Brekel, Huib Ovaa, Jacques Neefjes, Charlotte L. Zuur

Citations: 32 • 2017

Nivolumab, nabpaclitaxel, and carboplatin followed by risk/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial.

Ari J. Rosenberg, Nishant Agrawal, Alexander T. Pearson, Tanguy Y. Seiwert, Zhen Gooi, Elizabeth A. Blair, Daniel Thomas Ginat, Adam Howard, Jeffrey Chin, Sara Kochanny, Evgeny Izumchenko, Aditya Juloori, Daniel J. Haraf, Everett E. Vokes

Citations: 30 • 2021

HPV‐associated oropharyngeal cancer de‐escalation strategies and trials: Past failures and future promise

Kaveh Zakeri, Lara Dunn, Nancy Y. Lee

Citations: 24 • 2021

The rationale for HPV-related oropharyngeal cancer de-escalation treatment strategies

Małgorzata Wierzbicka, Krzysztof Szyfter, Piotr Milecki, Krzysztof Składowski, Rodryg Ramlau

Citations: 20 • 2015

Comprehensive literature review of randomized clinical trials examining novel treatment advances in patients with colon cancer

William Paul Skelton, Aaron J Franke, Atif Iqbal, Thomas J. George

Citations: 14 • 2020

Development and validation of generic heterogeneous fluoroimmunoassay for bioanalysis of bevacizumab and cetuximab monoclonal antibodies used for cancer immunotherapy

Mohammed A. Hamidaddin, Haitham AlRabiah, Ibrahim A. Darwısh

Citations: 5 • 2018

Have We Tipped the Balance in HPV-Associated Oropharyngeal Cancer?: The Patient-Experience Side of the De-Escalation Balance Scale

Jolie Ringash

Citations: 1 • 2021